Aggregate evidence quality | D (expert opinion and studies in children with T1DM and in adults with T2DM; no studies have been performed in children and adolescents with T2DM). |
Benefit | Diminishing the risk of progression of disease and deterioration resulting in hospitalization; prevention of microvascular complications of T2DM. |
Harm | Potential for hypoglycemia from overintensifying treatment to reach HbA1c target goals; cost of frequent testing and medical consultation; possible patient discomfort. |
Benefits-harms assessment | Preponderance of benefits over harms. |
Value judgments | Recommendation dictated by widely accepted standards of diabetic care. |
Role of patient preferences | Minimal; recommendation dictated by widely accepted standards of diabetic care. |
Exclusions | None. |
Intentional vagueness | Intentional vagueness in the recommendation as far as setting goals and intensifying treatment attributable to limited evidence. |
Policy level | Option. |
Aggregate evidence quality | D (expert opinion and studies in children with T1DM and in adults with T2DM; no studies have been performed in children and adolescents with T2DM). |
Benefit | Diminishing the risk of progression of disease and deterioration resulting in hospitalization; prevention of microvascular complications of T2DM. |
Harm | Potential for hypoglycemia from overintensifying treatment to reach HbA1c target goals; cost of frequent testing and medical consultation; possible patient discomfort. |
Benefits-harms assessment | Preponderance of benefits over harms. |
Value judgments | Recommendation dictated by widely accepted standards of diabetic care. |
Role of patient preferences | Minimal; recommendation dictated by widely accepted standards of diabetic care. |
Exclusions | None. |
Intentional vagueness | Intentional vagueness in the recommendation as far as setting goals and intensifying treatment attributable to limited evidence. |
Policy level | Option. |